Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Neurocrine Biosciences After Earnings Report

Related NBIX
US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data
UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation

In a report published Monday, Jefferies reiterated its Buy rating on Neurocrine Biosciences (NASDAQ: NBIX), and slightly raised its price target from $13.00 to $14.00.

Jefferies noted, “NBIX reported 4Q12 earnings per share and announced 2013 guidance. The next major catalyst for shares will be the data for ‘854 in movement disorders in May. We would be buyers ahead of these data and see significant upside potential as we can justify the entire valuation of NBIX on sales of elagolix for endometriosis.”

Neurocrine Biosciences closed on Friday at $10.84.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (NBIX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters